Hematologic Malignancies: Diagnosis, Prognosis and Management
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: 1 May 2026 | Viewed by 55
Special Issue Editors
Interests: follicular lymphoma; stem cell transplantation; prognostic factors
Special Issue Information
Dear Colleagues,
Recent advances in molecular diagnostics, targeted therapies, and immunotherapies including CAR T-cells have profoundly reshaped the landscape of hematologic malignancy treatment. However, significant challenges remain, including therapeutic resistance, disease relapse, and the need for more personalized prognostic tools.
This Special Issue will collate cutting-edge research and clinical insights that address these critical areas. We will highlight the latest developments in the use of genomic and proteomic biomarkers for precision diagnosis and risk stratification, as well as novel therapeutic approaches and strategies for managing treatment-related toxicities. We also welcome submissions on the evolving role of minimal residual disease (MRD) monitoring and the integration of artificial intelligence in patient care pathways.
We invite high-quality original articles and comprehensive reviews that advance our understanding of hematologic malignancies. We look forward to receiving your valuable contributions to this vital field of medicine.
Dr. Ádám Jona
Dr. Zsófia Miltényi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- malignant lymphoma
- treatment
- prognostication
- stem cell transplantation
- cellular therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
